The European Generic Medicines Association (EGA) is advocating for changes to regulatory framework of the European Union with respect to the marketing of generics and biosimilars in the European Union. The EGA is seeking to enhance tax and R&D incentives for generic and biosimilar research and clinical trials. The generic manufacturers are also seeking to expedite market authorizations by eliminating patent linkage and applying a harmonized single market approach to approvals.

More detailed information can be accessed at the following website: